| | | |
|
|
|
|
|
|
A Randomized, Placebo-Controlled, Double-Blind Trial of
the Effect of Combined Therapy with Deferoxamine and Deferiprone on Myocardial
Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance -Tanner et al.
2007 |
|
The leading cause of death in thalassaemia major patients is
cardiac complications secondary to iron overload. Ferriprox® has
been shown to remove cardiac iron, improving cardiac function
and patient survival. This study aims to determine if Ferriprox
in combination with desferoxamine, provides additional benefits
versus deferoxamine alone...More
|
| |
|
|
|
|
|
Effect of Enhanced Iron Chelation Therapy on Glucose
Metabolism in Patients with β-Thalassaemia Major -Farmaki et al.
2006 |
|
Endocrinopathies are the most common iron-induced complications
in thalassaemia major (TM) patients. Recent data have indicated
that deferiprone has greater ability than deferoxamine in
chelating intra-cellular iron and in preventing iron-induced
cardiac disease. (Farmaki, 2006)...More
|
| |
|
Survival of Medically Treated Thalassemia Patients in
Cyprus. Trends and Risk Factors Over the Period 1980-2004 -Telfer et al.
2006 |
|
Cyprus has a high carrier rate for thalassaemia major, and most
patients are born and treated exclusively on the island. This
makes Cypriot thalassaemia patients an excellent population to
study for trends and changes relating to survival. (Telfer, 2006)...More
|
| |
|
Myocardial Iron Loading in Patients with Thalassemia Major on
Deferoxamine Chelation -Tanner et al.
2006 |
|
Cardiac failure due to iron overload in the heart is the leading
cause of death in thalassaemia major patients. This study was
performed to evaluate the prevalence of myocardial iron overload as
well as decreased heart function in thalassaemia major patients
maintained on deferoxamine therapy. (Tanner, 2006)...More
|
| |
|
Cardiac morbidity and mortality in deferoximine or
deferiprone treated patients with thalassemia major - Borgna-Pignatti et al. 2006 |
|
The life expectancy of patients with thalassaemia major has
significantly increased in recent years. However, iron overload
of the heart remains the main cause of morbidity and mortality,
being responsible for more than half of all deaths...More
|
| |
|
Randomized controlled trial of deferiprone or
deferoximine in beta-thalassaemia major patients with asymptomatic myocardial
siderosis - Pennell et al. 2006 |
|
Cardiac disease is the cause of approximately 70 percent of
deaths in beta thalassaemia major. Cardiovascular magnetic
resonance (CMR) can measure cardiac iron deposition through the
magnetic relaxation parameter T2*...More
|
| |
|
Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease- Wood
et al. 2004 |
|
Cardiac T2* (magnetic resonance imaging relaxation parameter) is abnormally low in approximately 40% of adults with thalassemia major (TM), suggesting myocardial iron deposition, but it is unknown at what age this occurs....More
|
| |
| Comparative
effects of deferiprone and deferoxamine on survival and cardiac disease in
patients with thalassaemia major: a retrospective analysis -Piga et al.
2003 |
|
The leading cause of death for thalassaemia patients with iron
overload is iron-induced cardiac disease. Despite chelation
therapy with deferoxamine, 67% of thalassaemia patients die as a
result of cardiac problems (Borgna – Pignatti, 2003)...More
|
| |
| Comparison
of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial
iron concentrations and ventricular function in beta-thalassaemia - Anderson
et al. 2002 |
|
Currently more than 50% of patients with thalassaemia major die before the age of 35 years, predominantly from iron-induced heart failure. The efficacy of oral deferiprone in reducing myocardial iron concentrations is unknown. The objective of this study was to compare the effects of deferiprone and deferoxamine on myocardial iron concentrations and ventricular function in
beta-thalassaemia...More
|
| |
| The
Satety and effectiveness of Deferiprone in a large-scale, 3-year study in
Italian patients - Ceci et al. 2002 |
|
In 1997, the Italian Ministry of Health included Deferiprone in
the list of drugs to be used under controlled conditions,
permitting the use of the drug before Marketing Authorization
was issued by the EMEA...More
|
| |
| Deferiprone
versus Deferoxamine in Patients with Thalassaemia Major: A Randomized Clinical
Trial - Maggio et al. 2002 |
|
Deferoxamine is widely accepted as the standard Chelation
therapy. It requires patients to administer overnight
subcutaneous infusions that are painful and associated with
serious side effects...More
|
| |
|
Lack of progressive hepatic fibrosis during long-term therapy with
Deferiprone in subjects with transfusion-dependent beta-thalassaemia - Wanless
et al. 2002 |
|
Subjects with Thalassaemia often develop liver fibrosis. This
complication is known to depend particularly on the presence of
viral hepatitis but also on hepatic iron concentration, the
distribution of iron within the liver, and age...More
|
| |
|
|
|
